Most cases of high-grade serous ovarian cancer are not diagnosed until the disease has reached an advanced stage.
New research has uncovered immunological changes in some cases of high-grade serous ovarian cancer (HGSOC) following chemotherapy, which the authors say can help clinicians better understand the risk that a particular patient may experience an early recurrence.
The report was published in Frontiers in Immunology.
Most diagnoses of HGSOC are not made until the disease has already advanced, according to this study’s investigators. Chemotherapy is the standard treatment, but the authors say most patients (70%-80%) will experience a recurrence. The result is a 5-year survival rate of just 30% for patients with advanced-stage HGSOC.
Still, the authors said although some patients will experience recurrence within 6 months of their initial therapy, others do not see recurrence until 5 or 10 years after their initial treatment, highlighting the great need for a better understanding of which factors lead to early or late recurrences so investigators can target such mechanisms and thereby increase survival times. The authors suspected that chemotherapy response might be associated with a specific gene expression signature determined by the tumor microenvironment.
To investigate, they looked at tumor samples from 24 patients with HGSOC who underwent carboplatin and taxol chemotherapy. They compared samples taken prior to therapy to samples taken following therapy to see if gene expression signatures might correlate with recurrence rates and timing.
They found no notable link between gene expression signatures prior to chemotherapy and eventual patient outcomes. However, the samples taken after chemotherapy told a different story.
“[C]hemotherapy induced significant immunological changes in tumors from late recurrence patients, but had no impact on tumors from early recurrence patients,” they said.
In patients who would go on to have late recurrence, chemotherapy induced the downregulation of genes involved in cell proliferation and upregulation of genes involved in apoptosis, they found.
“This was not surprising, since it suggests that chemotherapy effectively induces cancer cell death in patients who would show good response, ie, delayed (instead of early) recurrence,” the authors said.
In patients with late recurrence, the authors found chemotherapy inverted the immune profile in the tumor microenvironment from a pro-tumor phenotype toward an antitumor immune response.
“To the best of our knowledge, this is the first time that a transcriptomic study in HGSOC patients showed that effective carboplatin and taxol chemotherapy induces an antitumor response alongside cancer cell death in good responders but not in poor responders,” they said.
The authors added that HGSOC has generally been seen as an immunologically “cold tumor,” meaning it is unlikely to respond to immunotherapy. However, their data show late-relapse cases have immunological changes after chemotherapy that makes the tumors “hot.”
“Therefore, our finding that carboplatin and taxol chemotherapy converts ovarian tumors from being ‘cold’ towards a ‘hot’ phenotype in patients with late recurrence suggests that these patients are more likely to benefit from immunotherapy,” they said, adding that their findings also suggest that new strategies are needed for patients likely to be poor responders to chemotherapy.
“Ultimately, this underscores the need for practicing personalized medicine to improve survival for ovarian cancer patients,” they concluded.
Reference
Adzibolosu N, Alvero AB, Ali-Fehmi R, et al. Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer. Front Immunol. Published online June 26, 2023. doi:10.3389/fimmu.2023.1204148
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces as AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More